Showing posts with label cash. Show all posts
Showing posts with label cash. Show all posts

Thursday, September 8, 2011

Dendreon Restructuring Call

Mitchell H. Gold, MD, Dendreon's CEO, led a analyst conference call to discuss restructuring plans. This follows the month-earlier announcement that Provenge sales were ramping slower than expected.

About 500 employees are being laid off, out of about 2000. Restructuring costs are estimated at $21 million, including $5 million in non-cash stock-based compensation.. Savings from restructuring are estimated at $120 million per year. Most of these employees were in training to be ready to meet the (previously expected) demand ramp. Presumably if demand accelerated again they would have to be rehired, and the savings would not accrue.

For most mid to long term investors the key question is long term demand. Revenues for August were reported at $22 million, up 16% from July, which would put July around $19 million. Given a similar $3 million ramp in September, Q3 income would be $66 million, but management stood by its refusal to guide on revenue other than to say that it expects it to ramp slowly quarter by quarter in the immediate future. $66 million is up 32% sequentially from $50 million in Q2, which would be tremendous had expectations not been raised so high earlier in the year.

Approval of Provenge in Europe was painted as a 2013 event, so no revenue help there is likely until 2014.

Analysts' questions went every which way at management's statement that $500 million in annual revenues, or $125 million per quarter, would get Dendreon to cash-flow break even (but not to GAAP profits). They also believe they have enough cash to reach that point. They had $674 million in cash at the end of next quarter, and $600 million on August 31. Cash use should decline now that the 3 Provenge facilities have been certified by the FDA.

Aside from restructuring, the major effort is in sales. The good news is that the reported time for reimbursement for Provenge has dropped to around 30 days, from prior reports of 60 days or more. That means medical organizations with cash flow issues could treat twice as many patients with the same amount of capital. Also, a concerted effort to make sure prescribers understand the Provenge label and reimbursement availability has been made and is ongoing. We will see if this all has an affect if management keeps reporting revenues on a monthly basis.

Management still believes that the $90,000 per patient price is not an obstacle, and that other prostate cancer drugs will not prevent Provenge from being prescribed within its label, since it is very safe, with almost no side effects, and the course of therapy is much quicker than for most cancer drugs.

There seems to be little fodder for short term momentum plays up or down right now. A lot of risk has been incorporated into the current stock price. A slow revenue ramp with flattening in 2012 would probably keep the price in a range. A faster ramp and better evidence that end demand really can ramp well above $500 million per year would justify a higher stock price, maybe substantially higher, but that could take several quarters to see.

Disclaimer: I have been long Dendreon since 2005, but buy and sell according to my analysis of prospects versus the market capitalization. I added Dendreon shares in August 2011 and last sold shares in April of 2010. I have no plans to buy or sell Dendreon in the near term.

See also: Dendreon Press Releases

Friday, July 11, 2008

Cash is King

The United States of America has a long history of booms financed largely by credit followed by periods of recession and limited credit. You don't have to be an economist to see these trends. You do have to be a calculating, unemotional investor to take advantage of them. Take the Kennedy family. They were doing pretty well during the 1920's, but Joseph Kennedy knew his history and economics. He cashed out well before the crash. Then, in the depth of the Depression, he went on a buying spree with the cash he had. Thus a family of little economic note went from the lower middle class to being one of the richest in America in a single generation. Only then did the political experience of the family, previously of account only in Boston, bloom into a dynasty of national importance.

There is nothing wrong with taking credit under appropriate circumstances. Between 1936 and 2003 buying a house on credit was a sound investment in most of the United States. Taking some credit to ease a business startup can be rewarding too. But even when these general rules applied, there were specific counterexamples. Buying a house in a city whose factories moved to Mexico or China, or even to Alabama, did not work out for a lot of people. Most small businesses fail or limp along.

You would think with the Internet stock bubble of the late 1990's in the rear view mirror that people would have been more cautious about buying McMansions on credit between 2002 and 2006. In the vast majority of cases, while the price of the house was an issue, the two main factors in the personal disasters were buying a house that was too big, and spending too much on luxuries (often fueled by additional loans).

For about a year and a half now we have been seeing the other side of the equation, a contraction of credit. The Federal Reserve was created to minimize the credit cycle, but it did a poor job at that starting when Alan Greenspan took over. Voodoo economics, the theory that markets always reach an equilibrium that has good results for humans, can only partly be blamed. Credit was created off the Federal Reserve's books, so to speak, and like Enron stockholders, the Fed acted like that was none of its business.

In 1928 Al Smith was the Democratic Party candidate for President. Herbert Hoover won by a landslide; he was already a national hero. The Dixie wing of the Democratic Party could not get the voters behind Smith, a Catholic whose only real political difference with Herbert Hoover was that he was for ending Prohibition (of the sale of alcohol). If Al Smith had won the election there would still have been a Great Depression. The Republican Party would have come to power in 1932, and as the credit cycle turned it would have established itself again as the party of Prosperity. History would be very different.

While we are in a credit crunch, cash is king. Unless you want to use your dollars to buy foreign assets, you can buy almost any investment cheap. Stocks, bonds, real estate, you name it.

True, if the U.S. or world economy collapses, you will look like a fool for not holding onto your cash. But if that happens, all bets are off; even cash may not save you. A collapse is not very likely. Parts of our economy, notably agriculture and manufacturing not related to construction, are doing quite well. Unless the Fed or Congress does something really stupid, there will be a bottom and then a liftoff period. No one will really be able to see the bottom until it is a quarter or two behind us.

Best bet in this environment? Stocks and bonds of well-established, profitable companies with global distribution networks. Buy what looks cheapest on a value basis; don't read too much into other people's selling, which is based on their liquidity needs and their fears. Figure this credit squeeze will last a while, which means spreading your conversion of cash into assets over time. Keep in mind that the important bottom is the credit bottom, not the stock market bottom.

And keep diversified.